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S196 Poster Session I(logrank p 5 0.003), and 89% for IPS score 5 0-1, 56% for IPS 5
2-3, and 24% for IPS 5 4-7 (logrank p\ 0.001). Response to DI-
CEP and relapse IPS were the only two factors that independently
predicted PFS and OS in multivariate analysis. Of the 26 patients
who relapsed following DICEP6HDM/ASCT, 7 (27%) achieved
subsequent long-term PFS of $ 3 years using radiotherapy
(n 5 1), chemotherapy and radiotherapy (n 5 2), or allogeneic
SCT (n 5 4).
DICEP-HDM/ASCT for relapsed/refractory Hodgkin lym-
phoma is associated with excellent stem cell mobilization capability
and favourable PFS and OS outcomes. These results compare
favourably to previously reported alternative regimens and require
validation in a prospective multi-centre clinical trial.115
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BEAM (Carmustine, etoposide, cytarabine, and melphalan) is the
most used conditioning regimen before autologous stem cell trans-
plant (ASCT) in lymphoma patients. However, relapse rate after
transplant is still a matter of concern. Therefore, new regimens
with a higher efficacy are particularly needed.
We designed a phase I-II study to evaluate the safety and the effi-
cacy of increasing doses of Bendamustine for the conditioning regi-
men to ASCT for resistant/relapsed lymphoma patients. As
a biological background, we performed in vitro experiments which
showed the synergistic activity of bendamustine with etoposide, ara-
cytin and melphalan in lymphoma cell lines.
Forty-four patients (median age 47 years) with resistant/relapsed
non-Hodgkin (29) or Hodgkin (15) lymphoma were consecutively
enrolled in the study. The new regimen consisted of increasing doses
of Bendamustine coupled with fixed doses of Etoposide (200mg/m2/
day on days -5 to -2), Cytarabine (400mg/m2 on days -5 to -2) and
Melphalan (140 mg/m2 on day -1) (BeEAM regimen). The study
was registered at EMEA with the EUDRACT no 2008-002736-
15. The starting dose of Bendamustine was 160 mg/m2/daily given
on days -7 and -6, which was then escalated according to the Fibo-
nacci’s increment rule until the onset of severe adverse events and/
or the attainment of the expected MTD, but not higher than 200
mg/m2.
The administration of Bendamustine was safe in all the 3 cohorts
of 3 patients. We then fixed the dose of Bendamustine 200 mg/m2 as
safe and effective for the Phase II study.
A median number of 5.68x106CD341/kg cells (range 2.4-15.5) col-
lected from peripheral bloodwas reinfused to patients. All patients en-
grafted, with a median time to ANC . 0.5x109/l of 10 days. Median
times to achieve a platelet count . 20x109/l and . 50x109/l were 13
and16days respectively.Twenty-twoout of 44 patients presented a fe-
ver of unknown origin. All patients received G-CSF after transplant
for a median time of 9 days (range: 8-25).
39/44 patients are evaluable for the response to treatment. After
a median follow-up of 14 months from transplant, 32/39 patients
are in complete remission, whereas 4/39 are in partial response. 3/
39 patients relapsed after a median time of 3 months from transplant.
Remarkably, 4/39 patients achieved the first complete remission af-
ter receiving the high-dose therapy with ASCT.
In conclusion, the new BeEAM regimen is safe and seems to have
a high efficacy in heavily pretreated lymphoma patients.116
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Mantle cell lymphoma (MCL) has a poor prognosis with a median
survival of 5 years based on conventional immunochemotherapy. In
spite of the high risk characteristics of the 160 patients of the Nordic
MCL2 Trial of 1.-line intensive immunochemotherapy followed by
BEAM and autologous stem cell transplantation (31% with high Ki-
67 expression, 19% blastoid/pleomorphic), the first results based on
three years median observation were encouraging, including no re-
lapses after 5 years1. In the present update based on median 5.6 years
observation, the 10-year overall survival (OS) is 58%. Late relapses
have decreased the 10-year event-free survival (EFS) and response
duration (RD) to 35% and 46%, respectively. An example of a late
relapse was an isolated CNS relapse in a patient otherwise in persis-
tent complete remission 9.5 years after initial treatment. The mantle
cell lymphoma International prognostic index (MIPI)2, previously
found of prognostic value in our cohort3, remained highly predictive
of OS, EFS and RD. Particularly theMIPI-biological, incorporating
Ki-67, identified 20% of the patients still relapse-free from 3.4 years
to now 9 years posttransplant. Amolecularmarker was available in 71
of the 145 responding patients who completed treatment and had
follow-up samples for minimal residual disease. Molecular response
duration of less than one year posttransplant corresponded to
a shorter clinical response duration (median 4.2 years) than molecu-
lar response duration . 1 year (median 9 years clinical response
duration). In conclusion, the 58% 10-year survival of this high-risk
cohort is still very encouraging, but late relapses do occur, warrant-
ing long-term control and trials of maintenance treatment in this
disease.
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MINIMIZING THE COST OF CURRENT INEFFECTIVE MOBILIZATIONS:
DOUBLING FILGRASTIM ON DAY 4 OF FILGRASTIM-ALONE MOBILIZA-
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Background: Autologous stem cell mobilization with colony stimu-
lating factors alone has a failure rate of approximately 20%. Plerixa-
for is a stem cell mobilizer effective in increasing the number of
peripheral CD34 cells collected by hematopoetic progenitor cell
apheresis (HPC-A) while reducing the number of HPC-A days in
